A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial

Trial Profile

A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Mycophenolate mofetil (Primary) ; Sirolimus (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary) ; Fludarabine
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 14 Aug 2012 Additional lead trial centres added as reported by ClinicalTrials.gov.
    • 16 Apr 2012 Planned end date changed from 1 Nov 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top